Literature DB >> 11602315

Protein-protein interactions in hematology and phage display.

B P Mullaney1, M G Pallavicini.   

Abstract

Phage display, which exploits fundamental tools and principles of immune repertoire diversity, antigen-antibody interactions, and clonal and immunologic selection, is used increasingly to advance experimental and clinical hematology. Phage display is based on the ability of bacteriophage to present engineered proteins on their surface coat. Diverse libraries of proteins such as peptides, antibody fragments, and protein domains corresponding to gene fragments or cDNAs may be displayed. Interactions between phage-displayed proteins and target antigens can be identified rapidly and characterized using high throughput methodologies. Peptide and gene fragment libraries are particularly useful to characterize binding interactions between proteins, such as ligand-receptor interactions. This approach allows rapid generation of human antibodies, often against nonimmunogenic, conserved proteins. Phage antibodies against surface and intracellular antigens are used as reagents for flow cytometry, in vivo imaging, and therapeutic targeting. Phage-derived antibodies also facilitate analyses of the humoral antibody response. Finally, cellular delivery of phage-displayed peptides and gene fragments can be used to modulate functional pathways and molecules in vitro and in vivo. The combinatorial power of phage display enables identification of candidate epitopes without knowledge of the protein interaction, a priori. Overall, these capabilities provide a versatile, high-throughput approach to develop tools and reagents useful for a plethora of experimental hematology applications. This paper focuses on current and future applications of antibody and epitope phage display technology in hematology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602315     DOI: 10.1016/s0301-472x(01)00693-2

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

Review 1.  Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.

Authors:  Joseph A Fraietta; Robert D Schwab; Marcela V Maus
Journal:  Semin Oncol       Date:  2016-02-09       Impact factor: 4.929

Review 2.  Display technologies: application for the discovery of drug and gene delivery agents.

Authors:  Anna Sergeeva; Mikhail G Kolonin; Jeffrey J Molldrem; Renata Pasqualini; Wadih Arap
Journal:  Adv Drug Deliv Rev       Date:  2006-10-06       Impact factor: 15.470

Review 3.  CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.

Authors:  Kristen B Long; Regina M Young; Alina C Boesteanu; Megan M Davis; J Joseph Melenhorst; Simon F Lacey; David A DeGaramo; Bruce L Levine; Joseph A Fraietta
Journal:  Front Immunol       Date:  2018-12-03       Impact factor: 7.561

4.  Assessing reliability of protein-protein interactions by integrative analysis of data in model organisms.

Authors:  Xiaotong Lin; Mei Liu; Xue-wen Chen
Journal:  BMC Bioinformatics       Date:  2009-04-29       Impact factor: 3.169

5.  What a polyclonal antibody sees in von Willebrand factor.

Authors:  Fen-Lai Tan; David Ginsburg
Journal:  Thromb Res       Date:  2007-07-05       Impact factor: 3.944

6.  A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2012-08-03       Impact factor: 5.531

7.  Mimotopes and proteome analyses using human genomic and cDNA epitope phage display.

Authors:  Mullaney P B; Marks D J; Pallavicini G M
Journal:  Comp Funct Genomics       Date:  2002
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.